Disease Domain | Count |
---|---|
Neoplasms | 2 |
Hemic and Lymphatic Diseases | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Therapeutic radiopharmaceuticals | 1 |
Autologous CAR-T | 1 |
Top 5 Target | Count |
---|---|
PSMA(Prostate-specific membrane antigen) | 1 |
CD22(CD22) | 1 |
Mechanism BRAF inhibitors [+8] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date01 Dec 2005 |
Target |
Mechanism DNA inhibitors [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date19 Dec 1978 |
Target- |
Mechanism PET imaging |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc. US |
First Approval Date24 Feb 1972 |
Start Date01 Aug 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Start Date01 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
177Lu HTK03170 ( PSMA ) | Prostatic cancer metastatic More | Phase 2 Clinical |
CLIC-2201 ( CD22 ) | Mantle-Cell Lymphoma More | Phase 1 |
Cisplatin ( DNA ) | Locally Advanced Head and Neck Squamous Cell Carcinoma More | Discontinued |
Sorafenib Tosylate ( BRAF x CRAF x FLT3 x PDGFRβ x RET x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit ) | Locally Advanced Head and Neck Squamous Cell Carcinoma More | Discontinued |
SODIUM FLUORIDE F-18 | Bone metastases More | Pending |